31 October, 2018
Skadden advised Innovent Biologics Inc., a world-class China-based biopharmaceutical company, on its HK $3.3 billion (US $421 million) global offering and listing on the Hong Kong Stock Exchange. Trading commenced on 31 October 2018.
The team was led by Hong Kong partner Julie Gao, with Of Counsels Antony Dapiran and Paloma Wang (Hong Kong), and associates Yiming Liu (Shanghai), Paul Mok (Hong Kong), Ming Kong (New York), William Casey (Palo Alto), Yiying Wang (Shanghai) and Nicole Yuen (Hong Kong).
